Immunotherapy of b-cell malignancies using anti-cd22 antibodies

Details Immunotherapy of b-cell malignancies using anti-cd22 antibodies Immunotherapy of b-cell malignancies using anti-cd22 antibodies

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 38/19 (2006.01) A61P 35/00 (2006.01) C07K 16/28 (2006.01)

Patent

CA 2373618

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

Les manifestations malignes de lymphocytes B, telles que le sous-type à lymphocytes B des lymphomes non hodgkiniens et de la leucémie lymphocytaire chronique, contribuent pour une grande part à la mortalité par cancer. La réponse des manifestations malignes de lymphocytes B à plusieurs formes de traitement est mitigée. Des méthodes traditionnelles de traitement des manifestations malignes des lymphocytes B, y compris la chimiothérapie et la radiothérapie, ont une efficacité limitée à cause d'effets secondaires toxiques. L'immunothérapie avec des anticorps anti-CD20 a également connu un succès limité. Cependant, l'utilisation d'anticorps se liant à l'antigène de CD22 ou CD19 représente un moyen efficace de traitement des manifestations malignes de lymphocytes B, telles que des formes indolentes et agressives de lymphomes de cellules B, et des formes aiguës et chroniques de leucémies lymphatiques. En outre, une immunothérapie avec des anticorps anti-CD22 et/ou anti-CD19 requiert des doses relativement faibles de protéines d'anticorps, et peut être utilisée efficacement dans des thérapies multimodales.

Affiliated with

Also associated with

Rating

Immunotherapy of b-cell malignancies using anti-cd22 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunotherapy of b-cell malignancies using anti-cd22 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunotherapy of b-cell malignancies using anti-cd22 antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1693533